Was it humans?
A great deal of peptide marketing rests on cell culture and rodent work. Those studies are how you generate a hypothesis, not how you confirm a benefit. Rodents heal differently, dose differently by weight, and are usually young, uninjured and genetically uniform. "Shown to accelerate healing" with a mouse study behind it is a sentence about mice.
Was there a control group, and were people blinded?
Without a control arm you cannot separate the intervention from time, regression to the mean, and the fact that someone who just spent money on their health also started sleeping more. Injectable interventions produce especially strong expectation effects. An open-label series of satisfied customers is the weakest form of evidence that still gets called evidence.
Was the outcome the one you care about?
A study can show a real change in a laboratory value while telling you nothing about whether you will feel or function better. Growth hormone secretagogues reliably raise IGF-1; that is a surrogate marker, and raising it is not the same as demonstrating better body composition, strength or healthspan in people your age. Ask what was actually measured, and how long for.
How many people, and who were they?
A trial of twelve young men for four weeks does not establish anything about a fifty-year-old woman over a year. Sample size sets how easily chance explains the result; the population sets who the result applies to. Both get quietly dropped in the retelling.
Who paid, and what is not being shown?
Funding does not invalidate a study, but it belongs in view. More important is what is missing: if a seller cites one positive study and there are four neutral ones, the citation is accurate and the impression is false. Absence of published harm is also not evidence of safety when nobody has looked systematically.
Can you actually get it lawfully?
The final question, and the one that ends most conversations. Some of the most heavily promoted peptides are not eligible for compounding by a 503A pharmacy. In that case the evidence debate is academic: no lawful supply exists for you, and what is being offered instead is a grey-market vial with a disclaimer on it.
Key points
- Humans, controls, real outcomes, adequate numbers, full picture, lawful supply.
- A surrogate marker moving is not a benefit demonstrated.
- If there is no lawful supply, the evidence question is moot.
AZZA Medical is not a medical provider and does not practice medicine. Medical services are provided exclusively by independently licensed physicians of our partner physician network and their affiliated professional entities.
Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
This is not emergency care. AZZA Medical does not provide urgent or emergency medical services. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.